India has developed a handheld, non-invasive brain injury scanner aimed at improving early detection of traumatic brain injuries, particularly in settings where advanced imaging facilities remain limited.
According to The Economic Times, the device called CEREBO uses near-infrared spectroscopy combined with machine learning to detect intracranial bleeding and edema within a minute. Traditional diagnostic tools such as the Glasgow Coma Scale often rely on subjective assessment, while CT and MRI scans require specialised infrastructure, trained personnel, and higher costs. CEREBO seeks to close this gap by offering a radiation-free and cost-effective alternative.
Developed by Bioscan Research in collaboration with ICMR-MDMS, AIIMS Bhopal, and NIMHANS Bengaluru, the device has been clinically validated and received regulatory approvals in India. It is currently available through the government e-marketplace. Dr. Rajeev Bahl, Director General of the Indian Council of Medical Research (ICMR), noted that the innovation originated from an IIT incubator and was supported by ICMR through its validation and health technology assessment for cost-effectiveness.
Designed for use in ambulances, rural health facilities, trauma centres, and disaster response scenarios, CEREBO can be deployed in regions where access to advanced imaging remains scarce. Its portability and rapid results are expected to strengthen frontline emergency response, reduce diagnostic delays, and improve patient outcomes in traumatic brain injury cases.
The introduction of CEREBO also signals a broader trend in India’s health technology ecosystem: the movement towards affordable, indigenous medical devices that combine AI-driven capabilities with field-ready design. Industry observers suggest that beyond domestic deployment, such solutions have potential applications in military medicine and global emergency care markets. For policymakers, the device represents progress towards bridging rural–urban healthcare disparities, while for investors and industry stakeholders it underscores the role of homegrown innovation in meeting critical healthcare challenges.
